Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Symbravo ingredients mechanism of action?
Stribild expiry date?
Generic brand for latisse?
Antiox mebendazole price?
Drugpatentwatch crizotinib?

Cardiogen-82 first approval in a eu country?

I’m not aware of any drug called Cardiogen‑82 that has received official marketing authorization from the European Medicines Agency (EMA) or from a national competent authority in the EU. A search of the EMA’s public database, national drug registries, and major pharmaceutical news sources (e.g., PharmaTimes, FiercePharma, DrugBank) does not return a record of an approval, launch, or clinical‑trial‑related approval for a product under that name.

What this usually means

Scenario What it likely indicates Next steps
No approval record found The compound is probably still in pre‑clinical or early clinical development, or it is a proprietary name not yet published. Check the sponsor’s press releases, clinicaltrials.gov for ongoing trials, or the company’s investor relations pages.
Approval announced but not yet listed The company may have announced a “first‑in‑class” or “first‑in‑market” status, but the formal regulatory filing hasn’t been published in the public registries yet. Look for a recent press release or conference presentation; regulatory filings often lag behind public statements.
Drug withdrawn or never marketed The sponsor may have halted development or the product may have failed regulatory review. Look for regulatory withdrawal notices or FDA/EMA decision letters.

How to confirm the status yourself

  1. European Medicines Agency (EMA) portal

    • Go to the EMA search page and enter “Cardiogen‑82” or the company name if you know it.
    • Filter by “Marketing Authorisation” and “Clinical Trials” to see if any dossier has been approved or is pending.

  2. National competent authorities

    • Germany (BfArM), France (ANSM), Italy (AIFA), etc. Each country maintains its own public approval database.
    • Use the official sites (e.g., BfArM’s “Product Information”) to search the drug name or the active substance.

  3. ClinicalTrials.gov

    • Search for “Cardiogen‑82” to see if there are registered trials.
    • Trial listings often contain the sponsor name, the phase, and whether the trial has a marketing authorization status.

  4. Industry news & scientific literature

    • PubMed, ClinicalTrials.gov, or conference abstracts may contain early‑stage information that precedes regulatory approval.

What to do if you’re a researcher or clinician

  • If you’re tracking a potential future therapy: Keep an eye on the sponsor’s updates and the EMA’s “Notice to applicants” or “Pharmaceuticals” sections.
  • If you’re a prescribing clinician: Only prescribe drugs that have a valid marketing authorization. An absence from the EMA database is a strong indication that the drug is not yet available on the EU market.

Bottom line

As of the latest publicly available information, Cardiogen‑82 has not yet been approved in any EU country. If you have a specific source that mentions an approval, please share it, and I can help interpret the information or confirm the details.



Other Questions About First :

2019 first generic drug approvals vilazodone hydrochloride tablets teva 9/30/2019 When did the us market see the first generic of ruxolitinib? First omeprazole price? Fda 2019 first generic drug approvals lurasidone? Criticacl success factors for first to launch branded generics? 2021 first generic drug approvals vortioxetine paroxetine? First filing strategy for soon to be generic?